A reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec – People on the move

By Nick Taylor

- Last updated on GMT

Related tags: Chairman, Carl icahn, Ceo, Biogen idec, President and ceo

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec.

George Whitney ​has been appointed as director of business development for bulk pharmaceutical products at Kyowa Hakko USA​. Whitney has more than 25 years experience in biotech, most recently at Lonza’s custom manufacturing group.

Astellas Pharma​ has changed two of the nominees it plans to put up for election to the board of OSI Pharmaceuticals​. John Gilly​, a director at NCI-Frederick, and Margaret Monaco​, the principal of Probus Advisors, are now Astellas’ nominees.

Jeffrey Kindler​, CEO of Pfizer, has been elected as board chairman of the Pharmaceutical Research and Manufacturers of America ​(PhRMA​). Kindler succeeds David Brennan, CEO of AstraZeneca.

Also, Christopher Viehbacher​, CEO of Sanofi-Aventis, was named as chairman-elect and John Lechleiter​, CEO of Eli Lilly, was appointed as board treasurer.

Rib-X Pharmaceuticals​ has named Mark Leuchtenberger ​as president and CEO. Leuchtenberger has previously worked at Targanta Therapeutics, Therion Biologics and Biogen. Susan Froshauer ​has also joined Rib-X as chief scientific officer.

Eric Rowinsky​ has been appointed to the board of directors at Biogen Idec​ after the biotech reached an agreement with investor Carl Icahn. Stephen Sherwin​, chairman of the Biotechnology Industry Association (BIO), has also joined the board of directors.

PhytoMedical Technologies​ has named James Lynch​ as president and CEO. Greg Wujek​, the outgoing president and CEO, will continue as a director on the company’s board.

Related topics: Markets & Regulations

Related news

Show more

Follow us

Products

View more

Webinars